Brehm TT, Pfefferle S, von Possel R, Karolyi M, Zoufaly A, Wichmann D, Kobbe R, Emmerich P, N?rz D, Aepfelbacher M, Schulze Zur Wiesch J, Addo MM, Schmiedel S, L?tgehetmann M. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. J Med Virol. 2022 10; 94(10):5038-5043.

Ejemel M, Smith TG, Greenberg L, Carson WC, Lowe D, Yang Y, Jackson FR, Morgan CN, Martin BE, Kling C, Hutson CL, Gallardo-Romero N, Ellison JA, Moore S, Buzby A, Sullivan-Bolyai J, Klempner M, Wang Y. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 06 07; 12(1):9403.

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart?nez-L?pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 08 11; 387(6):495-505.

Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.

Szydlowski M, Garbicz F, Jablonska E, G?rniak P, Komar D, Pyrzynska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Golas A, Domagala J, Winiarska M, Graczyk-Jarzynka A, Bialopiotrowicz E, Polak A, Barankiewicz J, Pula B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brz?zka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczynski P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. 2021 12 01; 81(23):6029-6043.

Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen???CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 08 21; 398(10301):665-674.

Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampuria DA, Gries KS, Qi M, Bahlis N, Ito S. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Ann Hematol. 2021 Apr; 100(4):1065-1077.

Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021 Feb 04; 22(4).

Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anticancer Drugs. 2021 01 01; 32(1):74-81.

Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):188-198.e2.